Tecovirimat

(TPOXX®)

TPOXX®

Drug updated on 11/16/2023

Dosage FormCapsule (oral: 200 mg); Injection (intravenous: 200mg/20 mL)
Drug ClassOrthopoxvirus VP37 envelope wrapping protein inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • TPOXX is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 13 kg.

Product Monograph / Prescribing Information

Document TitleYearSource
TPOXX (tecovirimat) Prescribing Information.2022Siga Technologies Inc., Corvallis, OR

Systematic Reviews / Meta-Analyses